Eli Lilly is deploying its cash pile into untested drug development strategies, including an “App Store” for scientists, as the pharma group aims to shield itself from the expiry of patents on its blockbuster weight-loss drugs.
The Indianapolis-headquartered group last year launched its own data centre with 1,016 advanced Blackwell computer chips, bought from semiconductor giant Nvidia, as part of a push into AI as a tool for drug discovery.
Lilly’s computing investment included a new collaboration with about 100 smaller biotechs, allowing them to work with AI models in return for their data, chief executive Dave Ricks told the FT in an interview.
您已阅读11%（653字），剩余89%（5315字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。